Keywords: UK, NICE, Final guidance, Takeda, Mepact, AstraZeneca, Brilique, Brilinta, Osteosarcoma, ACS, coronary syndrome

UK’s NICE final guidance backs Takeda’s Mepact and AstraZeneca’s Brilique

Article | 26 October 2011

Print This

The UK’s National Institute for Health and Clinical Excellence (NICE) issued two final guidances this morning, reversing a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in